Spago Nanomedical Seeks Shareholder Approval for Nasdaq First North Delisting

• Spago Nanomedical shareholders will vote November 19, 2026, on a proposed delisting from Nasdaq First North Growth Market.
• The board backs delisting to attract long-term specialist investors for Tumorad’s planned Phase IIa trial.
• Shareholders representing approximately 65% of shares and votes intend to support the proposal.
• Approval requires 90% of votes cast and shares represented; shareholders holding a majority of other votes must not oppose the controlling shareholder.
• Subject to Nasdaq approval, the delisting application is planned no earlier than January 25, 2027, with trading expected to end in February.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spago Nanomedical AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.